Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Currently submitted to: JMIR Cancer

Date Submitted: Nov 27, 2019
Open Peer Review Period: Nov 27, 2019 - Jan 22, 2020
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer-Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Clinical, biochemical and radiological profile of bone metstases along with pain score and quality of life in solid malignancies at a tertiary care hospital in North India: Two year prospective study

  • HakimIrfan Showkat; 
  • G M Bhat; 
  • Arif Sarmast; 
  • Basharat Jan; 
  • Nazir Khan; 
  • Irfan Robbani; 
  • Sheikh Aijaz Azeez; 

ABSTRACT

Background:

AIM:To study the clinical, biochemical , radioligical profile of bone metastases along with distribution of skeletal metastases with management strategies and effect on quality of life

Objective:

AIM:To study the clinical, biochemical , radioligical profile of bone metastases along with distribution of skeletal metastases with management strategies and effect on quality of life

Methods:

MATERIAL & METHODS:This is a Two year prospective study from August 2013 to August 2015.Patients with a proven malignancy with bone scan positive metastatic skeletal lesions were taken and the clinical, biochemical & radiological manifestations of were analysed.Pain score by visual analogue score (VAS) both pre-treatment and post treatment were noted. Quality of life was noted at the baseline using European Organization for Research and Treatment of Cancer Quality of Life Group (EORTC) -Q30 questionnaire.

Results:

It was observed that majority of patients were males (58.8%).Bone metastases was most common in lung malignancy (30.4%) followed by carcinoma prostate (19.2%). Carcinoma breast was the third most common malignancy (18.8%) and most common malignancy with bone metastases in females. Pain was the most common presentation (83.6%).Alkaline phosphatase was raised in 80 % of cases & lactate Dehydrogenase was high in 92.4%.Osteolytic lesions were seen in 56.4% cases, osteosclerotic/osteoblastic in 32.4% while 11.2% cases had mixed lesions. Target X-ray imaging was positive in 46.8%, computed tomography (CT) scan 86.6%,magnetic resonance imaging (MRI) 81.4%,positron emission tomography (PET/CT) scan 93.3%. Non-Opiod analgesics were commonly used in 83.2% cases followed by Bisphosphonates in 82% .Pain score as per VAS scale improved significantly in all cases of bone metastases post intervention.Quality of life as per EORTC-30 questionnaire was impaired significantly in all cases with 86% cases having moderate to severe impairment.

Conclusions:

It was observed that majority of patients were males (58.8%).Bone metastases was most common in lung malignancy (30.4%) followed by carcinoma prostate (19.2%). Carcinoma breast was the third most common malignancy (18.8%) and most common malignancy with bone metastases in females. Pain was the most common presentation (83.6%).Alkaline phosphatase was raised in 80 % of cases & lactate Dehydrogenase was high in 92.4%.Osteolytic lesions were seen in 56.4% cases, osteosclerotic/osteoblastic in 32.4% while 11.2% cases had mixed lesions. Target X-ray imaging was positive in 46.8%, computed tomography (CT) scan 86.6%,magnetic resonance imaging (MRI) 81.4%,positron emission tomography (PET/CT) scan 93.3%. Non-Opiod analgesics were commonly used in 83.2% cases followed by Bisphosphonates in 82% .Pain score as per VAS scale improved significantly in all cases of bone metastases post intervention.Quality of life as per EORTC-30 questionnaire was impaired significantly in all cases with 86% cases having moderate to severe impairment.


 Citation

Please cite as:

Showkat H, Bhat GM, Sarmast A, Jan B, Khan N, Robbani I, Azeez SA

Clinical, biochemical and radiological profile of bone metstases along with pain score and quality of life in solid malignancies at a tertiary care hospital in North India: Two year prospective study

JMIR Preprints. 27/11/2019:17228

DOI: 10.2196/preprints.17228

URL: https://preprints.jmir.org/preprint/17228

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.